

Supplementary Figure S1. Schematic diagram of the SNHG15/miR-370-3p regulatory network during the development of atherosclerosis



Supplementary Figure S2. Biological effects of down-regulated expression of SNHG15 on control cells. **A –** Transfection efficiency of si-SNHG15. One-way ANOVA, F (DFn, Dfd) = 21.4 (2, 12). **B** – In the control group, transfection with si-SNHG15 induced a decrease in migrating cells. One-way ANOVA, F (DFn, Dfd) = 40.26 (2, 12). **C** – Images of Transwell assay. **D** – Inhibition of SNHG15 resulted in decreased cell viability in the control group. **E** – Inhibition of SNHG15 resulted in the contraction phenotype to the secretory phenotype transformation of control cells. α-SMA, one-way ANOVA, F (DFn, Dfd) = 33.39 (2, 12). OPN, one-way ANOVA, F (DFn, Dfd) = 27.58 (2, 12). **F** – Downregulation of SNHG15 attenuated the inflammatory response of the cells. TNF-α, one-way ANOVA, F (DFn, Dfd) = 143.8 (2, 12). IL-1β, one-way ANOVA, F (DFn, Dfd) = 155.7 (2, 12). IL-6, one-way ANOVA, F (DFn, Dfd) = 150.4 (2, 12). **G** – Inhibition of SNHG15 can upregulate the expression of miR-370-3p. One-way ANOVA, F (DFn, Dfd) = 21.94 (2, 12). **H** – Inhibition of SNHG15 can downregulate the expression of FOXO1. One-way ANOVA, F (DFn, Dfd) = 41.82 (2, 12). *** $P < 0.001$ vs. the control group